M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
124 deals · US$156bndisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Feb 2025 | Instinct Bio Technical Company | – | Relativity Acquisition Sponsor | Merger | Pending | 225.0 | Biotech | Hunter Taubman Fischer & Li (sell-side)Chardan (sell-side)Loeb & Loeb (buy-side)Ogier (buy-side) |
| Jul 2025 | DiamiR Biosciences Corp. | – | Aptorum Group | Merger | Completed | – | Diagnostics+1 | H.C. Wainwright & Co. (sell-side) |
| Oct 2025 | Astria Therapeutics | – | BioCryst Pharmaceuticals | Acquisition | Completed | 700.0 | Biotech+2 | Evercore (sell-side)Sidley Austin (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side) |
| Oct 2025 | Avidity Biosciences | – | Novartis | Acquisition | Announced | 11,000.0 | Biotech+2 | Goldman Sachs (sell-side)Barclays (sell-side)Kirkland & Ellis (sell-side)Covington & Burling (buy-side)Freshfields (buy-side)Gordon Dyal & Co. (buy-side) |
| Nov 2025 | Aptose Biosciences | – | HS North America | Acquisition | Announced | – | Biotech+2 | Locust Walk (sell-side)Stikeman Elliott (buy-side) |
| Dec 2025 | MindWave Innovations | – | Apimeds Pharmaceuticals US | Merger | Completed | – | Biotech+1 | Duane Morris (sell-side)Nelson Mullins Riley & Scarborough (buy-side) |
| Dec 2025 | Generation Bio Co. | – | XRA 7 Corp. | Acquisition | Announced | – | Biotech+1 | TD Securities (sell-side)WilmerHale (sell-side)Gibson Dunn (buy-side) |
| Dec 2025 | Amicus Therapeutics | – | BioMarin | Acquisition | Announced | 4,800.0 | Biotech+2 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Kirkland & Ellis (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side) |
| Dec 2025 | Dynavax Technologies | – | Sanofi | Acquisition | Announced | 2,200.0 | Biotech+1 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Cooley (sell-side)Weil, Gotshal & Manges (buy-side) |
| 2026 | Calytrix Bio | – | Eli Lilly | Acquisition | Announced | 1,500.0 | Biotech | Centerview Partners (sell-side) |
| 2026 | AttaiBeckley | – | Eli Lilly and Company | Acquisition | Announced | 3,800.0 | Biotech+2 | Moelis & Company (sell-side) |
| 2026 | FireFly Biologics | – | J&J | Acquisition | Announced | 1,000.0 | Biotech+1 | Centerview Partners (sell-side) |
| Jan 2026 | Dark Blue Therapeutics | – | Amgen | Acquisition | Completed | 840.0 | Biotech+2 | Goodwin (sell-side)BofA Securities (sell-side) |
| Jan 2026 | Mersana Therapeutics | – | Day One Biopharmaceuticals | Acquisition | Completed | – | Biotech+2 | TD Securities (sell-side)WilmerHale (sell-side)Gordon Dyal & Co. (buy-side)Fenwick & West (buy-side) |
| Jan 2026 | Ventyx Biosciences | – | Eli Lilly and Company | Acquisition | Announced | 1,200.0 | Biotech+2 | Jefferies (sell-side)Moelis & Company (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Ropes & Gray (buy-side) |
| Jan 2026 | InduPro Therapeutics | – | Eli Lilly and Company | Stake | Announced | – | Biotech+2 | Freshfields (buy-side) |
| Jan 2026 | SL Bio | – | Horizon Space Acquisition II Corp. | Merger | Announced | 5,568.0 | Biotech | VCL Law (sell-side)Ogier (sell-side)King Kee Appraisal and Advisory (buy-side)Robinson & Cole (buy-side)Maples Group (buy-side) |
| Jan 2026 | AbelZeta's 50% share of China development and commercialisation rights to C-CAR031 | AbelZeta | AstraZeneca | Asset sale | Announced | 630.0 | Biotech+2 | Davis Polk (sell-side) |
| Jan 2026 | RAPT Therapeutics | – | GSK | Acquisition | Announced | 2,200.0 | Biotech+1 | J.P. Morgan (sell-side)Cooley (sell-side)Latham & Watkins (sell-side)Evercore (buy-side)A&O Shearman (buy-side) |
| Jan 2026 | Repare Therapeutics | – | XenoTherapeutics | Acquisition | Completed | – | Biotech+1 | Cooley (sell-side)Stikeman Elliott (sell-side) |
| Feb 2026 | PrimeGen US | – | DT Cloud Star Acquisition | Merger | Announced | 1,500.0 | Biotech+1 | A.G.P./Alliance Global Partners (sell-side)Sichenzia Ross Ference Carmel (sell-side)Loeb & Loeb (buy-side) |
| Feb 2026 | Orna Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 2,400.0 | Biotech+1 | Lazard (sell-side)Goodwin (sell-side)Paul, Weiss (buy-side) |
| Feb 2026 | Avadel Pharmaceuticals | – | Alkermes | Scheme | Completed | – | Pharma+1 | Goldman Sachs (sell-side)Morgan Stanley (sell-side)J.P. Morgan (buy-side) |
| Feb 2026 | Faeth Therapeutics | – | Sensei Biotherapeutics | Acquisition | Completed | – | Biotech+2 | Cooley (sell-side)Lucid Capital Markets (buy-side)Sidley Austin (buy-side) |
| Feb 2026 | Arcellx | – | Gilead Sciences | Acquisition | Announced | 7,800.0 | Biotech+2 | Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Morgan Stanley (buy-side)Ropes & Gray (buy-side)Innisfree M&A (buy-side) |
| Feb 2026 | 35Pharma | – | GSK | Acquisition | Announced | 950.0 | Biotech+1 | Cooley (sell-side)Centerview Partners (sell-side)Paul, Weiss (buy-side) |
| Feb 2026 | AiCuris Anti-infective Cures AG | – | Veloxis Pharmaceuticals | Acquisition | Announced | 913.0 | Pharma+1 | Gibson Dunn (sell-side)Freshfields (buy-side) |
| Feb 2026 | Precision NeuroMed | – | Brainlab SE | Stake | Completed | – | Biotech+2 | Sidley Austin (sell-side) |
| Mar 2026 | Transcend Therapeutics | – | Otsuka | Acquisition | Announced | 700.0 | Biotech+2 | Kirkland & Ellis (sell-side)Goodwin (sell-side)Centerview Partners (sell-side)Skadden, Arps, Slate, Meagher & Flom (buy-side) |
| Mar 2026 | Cullgen | – | Gyre Therapeutics | Acquisition | Pending | 300.0 | Biotech+1 | Mintz (sell-side)Moelis & Company (buy-side)Gibson Dunn (buy-side) |
| Mar 2026 | Candid Therapeutics | – | Rallybio | Acquisition | Pending | – | Biotech+1 | Wedbush Securities (sell-side)Cooley (sell-side)Evercore (buy-side)Citizens JMP (buy-side)Ropes & Gray (buy-side) |
| Mar 2026 | Unleash-owned rights to UIO-524, UIO-525 and UIO-526 | Unleash Immuno Oncolytics | TransCode Therapeutics | Asset sale | Pending | – | Biotech+2 | Tungsten Advisors |
| Mar 2026 | Lisata Therapeutics | – | Kuva Labs | Acquisition | Pending | – | Biotech+2 | Mintz (sell-side)H.C. Wainwright & Co. (sell-side)Goodwin (buy-side)Campaign Management (buy-side) |
| Mar 2026 | Day One Biopharmaceuticals | – | Servier | Acquisition | Pending | 2,500.0 | Biotech+2 | Centerview Partners (sell-side)Fenwick & West (sell-side)Goldman Sachs (buy-side)Baker McKenzie (buy-side)Innisfree M&A (buy-side) |
| Mar 2026 | Pikavation | Synnovation | Novartis | Acquisition | Announced | 2,000.0 | Biotech+2 | Goodwin (sell-side)Centerview Partners (sell-side) |
| Mar 2026 | Ouro Medicines | – | Gilead | Acquisition | Announced | 1,675.0 | Biotech+1 | Paul, WeissGoodwin (sell-side)Centerview Partners (buy-side) |
| Mar 2026 | Terns Pharmaceuticals | – | Merck & Co. | Acquisition | Announced | 6,700.0 | Biotech+2 | Centerview Partners (sell-side)Freshfields (sell-side)Jefferies (sell-side)Covington & Burling (buy-side)Gibson Dunn (buy-side) |
| Mar 2026 | Eos SENOLYTIX | – | Pulmatrix | Merger | Announced | – | Biotech+1 | Palladium Capital Group (buy-side)Evolution Venture Partners (sell-side)Wilk Auslander (sell-side)Gemini Valuation Services (buy-side)Haynes Boone (buy-side) |
| Mar 2026 | AnaptysBio outstanding common stock | – | AnaptysBio | Buy-back | Announced | 100.0 | Biotech+1 | Piper Sandler (buy-side) |
| Mar 2026 | Kezar Life Sciences | – | Aurinia Pharmaceuticals | Acquisition | Announced | 51.5 | Biotech+1 | TD Securities (sell-side)Cooley (sell-side) |
| Mar 2026 | Apellis Pharmaceuticals | – | Biogen | Acquisition | Announced | 5,600.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side) |
| Mar 2026 | Centessa Pharmaceuticals | – | Eli Lilly and Company | Scheme | Pending | 6,300.0 | Biotech+1 | Centerview Partners (sell-side)Jefferies (sell-side)Goodwin (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Modeyso commercial sales royalties | Former Oncoceutics Inc. securityholders | HealthCare Royalty | Asset sale | Announced | – | Specialty finance and leasing+3 | Latham & Watkins (sell-side) |
| Apr 2026 | Exclusive global rights to TAK-063 (balipodect) | Takeda Pharmaceutical Co. | Axsome Therapeutics | Asset sale | Completed | – | Pharma+1 | Sidley Austin (buy-side) |
| Apr 2026 | Soleno Therapeutics | – | Neurocrine Biosciences | Acquisition | Completed | 2,900.0 | Biotech+2 | Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side) |
| Apr 2026 | Tubulis | EQT Life Sciences (LSP 7 fund) | Gilead Sciences | Acquisition | Announced | 3,150.0 | Biotech+2 | Goodwin (sell-side)J.P. Morgan (sell-side)CMS (sell-side)Centerview Partners (buy-side)Allen & Company (buy-side)Covington & Burling (buy-side)Arnold & Porter (buy-side)Venable (buy-side) |
| Apr 2026 | CrossBridge Bio | – | Eli Lilly and Company | Acquisition | Announced | 300.0 | Biotech+2 | Cooley (sell-side) |
| Apr 2026 | Obsidian Therapeutics | – | Galera Therapeutics | Merger | Completed | 413.5 | Biotech+2 | Goodwin (sell-side)Sidley Austin (buy-side)Leerink Partners (sell-side)Lucid Capital Markets (buy-side) |
| Apr 2026 | Neurona Therapeutics | – | UCB | Acquisition | Announced | 650.0 | Biotech+2 | Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side) |
| Apr 2026 | Kelonia Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 7,000.0 | Biotech+2 | Goodwin (sell-side)Jefferies (sell-side)Kirkland & Ellis (buy-side) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.